Boston Scientific Options Volume Surges on Large Bullish Bet for Year-End

Options trading in Boston Scientific Corporation (BSX) saw a dramatic spike on September 1, driven by a large, bullish bet that the medical device company's stock will recover by the end of 2026. The activity signals institutional confidence in a rebound for the stock, which has underperformed significantly over the past year.

A Closer Look at the Trade

Total options volume reached 118,890 contracts, with call options, which are typically bets on a price increase, accounting for an overwhelming 113,223 of those trades. The centerpiece of the activity was a massive vertical call spread targeting the December 18, 2026, expiration.

• The Structure: The trade involved buying 50,072 contracts of the $60 strike call and simultaneously selling 50,072 contracts of the $75 strike call.
• New Positions: Trading volume for these contracts far exceeded the existing open interest (9,072 for the $60 call and 1,196 for the $75 call), confirming this was new positioning rather than the closing of old trades.

This type of spread is a common institutional strategy that profits if the stock price rises into a specific range, while limiting both potential gains and losses. It points to a calculated bet on a meaningful, but not unlimited, rally.

Market Implications

Ad

The trade structure suggests traders expect Boston Scientific's stock, which was trading at $48.09, to rise above $60 per share by the end of the year. The maximum profit for the trade is realized if the stock is at or above $75 at expiration. This target range represents a potential gain of between 25% and 56% from its current price.

The large-scale establishment of this call spread also impacted the stock's volatility metrics. Three-month implied volatility fell by 1.70 points to 41.23%, indicating that options sellers see less risk of extreme price swings in the near term. This often occurs as market makers who facilitate large call trades hedge their exposure by buying the underlying stock, which can dampen volatility.

Context for Investors

This bullish positioning comes after a difficult period for Boston Scientific, with its stock down 54.2% over the last 12 months from an all-time high of $109.50. The lower strike of the call spread at $60 aligns with the consensus analyst price targets, which cluster in the $60–$63 range.

While the options market is signaling a potential turnaround, investors are also weighing a recent cybersecurity incident that has disrupted the company's global operations. Any updates on that situation or future earnings reports will likely serve as key catalysts for the stock's performance heading into the expiration of this significant options position.